Navigation Links
Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
Date:4/1/2008

ccelerating the growth of InnerCool's temperature modulation business in an efficient and cost-effective manner by establishing relationships with existing specialized international sales organizations."

"We are well positioned to successfully initiate marketing and selling the CoolBlue system in Austria, Switzerland and Germany," stated Reinhold Eder, Chief Executive Officer of Euromed, "and we look forward to expanding our distribution activities to include InnerCool's next-generation RapidBlue system when it becomes available later in the year. We believe InnerCool is the only company positioned to offer a comprehensive portfolio of best-in-class temperature modulation solutions for physicians and healthcare providers in this rapidly expanding therapeutic area."

InnerCool's Surface and Endovascular Temperature Modulation Systems

InnerCool's new CoolBlue(TM) surface temperature modulation system, which includes a console and a disposable CoolBlue vest with upper thigh pads, is designed to provide a tool for use in less acute patients or in clinical settings best suited to prolonged temperature management. InnerCool's CoolBlue vest and thigh pads wrap the body without requiring any adhesives to stick to the skin and produce cooling rates of around 1 degree C per hour, i.e. similar to those of currently-marketed surface cooling systems and endovascular systems using inflatable balloon-based catheters. InnerCool's CoolBlue external or surface-based temperature modulation system is designed to cool or warm patients from outside of their bodies and is intended for use in less acute settings such as in-hospital fever management.

InnerCool's next-generation RapidBlue(TM) system for high-performance endovascular temperature modulation is expected to receive FDA clearance in the second quarter 2008, and to initially have the same clearance as its current Celsius Control(TM) System. The RapidBlue system includes a programmable console with an enh
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
2. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
3. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
4. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
5. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
6. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
7. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
8. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
9. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
10. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
11. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015  Traverse Biosciences announced ... research and development agreement (CRADA) with Aratana Therapeutics ... development of TRB-N0224 for the treatment and control ... and cats.  Traverse Biosciences has also granted Aratana ... treatment and control of periodontal disease in companion ...
(Date:5/4/2015)... /PRNewswire/ - The Fight Against Cancer Innovation Trust ... the formation of Turnstone Biologics Inc. (Turnstone), a ... that harness the patient,s own immune system. ... the Children,s Hospital of Eastern Ontario ... Ontario Institute for Cancer Research (OICR), the Ottawa ...
(Date:5/4/2015)... MA (PRWEB) May 04, 2015 ... for drug discovery and life science research, today ... , the latest version of its enterprise solution ... biopharma R&D enables more efficient discovery and development ... approach to integrate and address protein optimization and ...
(Date:5/4/2015)... , May 4, 2015  Soligenix, Inc. (OTCQB: SNGX) ... products that address unmet medical needs in the areas ... will be presenting preclinical data from three of its ... Science and Technology Conference on May 12-14, 2015 to ... 701 Convention Plaza, St. Louis MO ...
Breaking Biology Technology:Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12
... GLASGOW, Scotland, Sept. 3 Leading neurosurgical ... in neurosurgical,diagnostic and treatment devices, along with ... and efficient at the European,Association of Neurosurgical ... than 1,000 neurosurgeons and related medical professionals,will ...
... PARIS, September 2 Sanofi-aventis announced,today that ... 25 and STEEPLE,studies confirm clear net clinical ... infarction (STEMI) for Lovenox(R) vs,Unfractionnated Heparin (UFH). ... year results were presented during,hotline sessions at ...
... Standards and Technology (NIST) have developed two ... validate the performance of analytic instruments that ... Recent years have seen a significant increase ... analytic techniques. Researchers can detect, measure and ...
Cached Biology Technology:Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 2Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 3Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 2New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 3New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 5Fluorescent glass SRMs are new tool for spectroscopy 2
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications ... a global provider of Software Defined Network Architecture (ET ... announced total revenue of approximately $20.4 million for the ... restated $19.5 million for the year ended December 31, ... 2014, the Company had completed its multi-year transition away ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... designated FV-100, which could alleviate the suffering of millions of ... stage of clinical testing in patients. Developed and ... clinical trial with FV-100 has recently been initiated in America. ... to 10,000 times more potent than existing treatments in early ...
... international team of scientists has proposed a set of ... reefs from ultimate destruction. Their proposal is being ... Indonesia, where leaders of six regional governments plus Australia ... largest-ever marine reserve in world history, the Coral Triangle ...
... the world,s second largest fish hide out for ... online on May 7th in Current Biology , ... of the iconic species and highlights just how little ... animals, the researchers said. "While commonly sighted in ...
Cached Biology News:Clinical trials for shingles drug take an important step forward 2Rules proposed to save the world's coral reefs 2Rules proposed to save the world's coral reefs 3Disappearing act of world's second largest fish explained 2
... L sample. Ideal for small volume applications, including pediatric, neonatal, geriatric, general adult, veterinary and experimental ... 3 minutes after turn-on. ... ... ...
Human/Mouse/Rat LAR Affinity Purified PAb...
X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
APG5 autophagy 5-like (S. cerevisiae)...
Biology Products: